FIRST RESPONDER
Memorandum of Agreement: For the Use of Nasal Naloxone by First Responders under Massachusetts Statewide Treatment Protocols

This Agreement is made and entered into on July 30, 2014 and is between
Alexander Y. Walley, MD, MSc, hereinafter known as “the medical director”; and
Massachusetts State Police Department, hereinafter known as “the FIRST RESPONDER agency.”

This Agreement is required pursuant to Massachusetts Department of Public Health regulations 105 CMR 171.000 (Office of Emergency Medical Services training regulations) for FIRST RESPONDER agencies that elect to implement a program for the use of Intranasal Naloxone in accordance with 105 CMR 700.003(D) (Drug Control Program regulations). First Responders employed by the FIRST RESPONDER agency will function under the medical control supervision of a physician Medical Director.

This Agreement is in place for the purpose of implementing a Nasal Naloxone Rescue Kit program (“program”).

THEREFORE THE PARTIES NOW MUTUALLY AGREE AS FOLLOWS:

The Medical Director Agrees;

1. To assume responsibility for all medical control aspects of the program and ensure that the administration of the program is in compliance with 105 CMR 171.000, and First Responders are administering Nasal Naloxone in accordance with the applicable Statewide Treatment Protocols, 105 CMR 171.000 (Treatment protocols, quality assurance);

2. To approve training programs for the use of Nasal Naloxone which meet the minimum standards established by the Department’s Administrative Requirement 2-100 and are in accordance with applicable Statewide Treatment Protocols, pursuant to 105 CMR 171.000 (Training);

3. To establish policies for the proper acquisition, storage, replacement, and disposal of the Nasal Naloxone rescue kits (See Amendment A) (Acquisition and replacement of devices);

4. To authorize the purchase of nasal naloxone rescue kits by the FIRST RESPONDER agency under his/her medical license (Acquisition and replacement of devices).

5. To complete and file an Application for Massachusetts Controlled Substances Registration (MCSR) for municipalities and non-municipal public agencies for use of naloxone in accordance with the Controlled Substances Act, M.G.L. Chapter 94C. Form available at: http://www.mass.gov/eohhs/docs/dph/quality/drugcontrol/naloxone-nerve-antidote-epi-form.pdf (Acquisition and replacement of devices).
FIRST RESPONDER
Memorandum of Agreement: For the Use of Nasal Naloxone by First Responders under Massachusetts Statewide Treatment Protocols

The FIRST RESPONDER agency Agrees;

1. To designate one qualified officer to serve as a liaison to the Medical Director and FIRST RESPONDER agency leader of the Nasal Naloxone Rescue Kit Program;

2. To participate in all quality assurance and or remediation procedures established by the Medical Director (Quality assurance);

3. To ensure First Responders complete initial and refresher training in cardiopulmonary resuscitation in accordance with the First Responder Training Regulations, at 105 CMR 171.000 (Training, treatment protocols);

4. To ensure all First Responders within the agency successfully complete training programs approved by the Medical Director for the use of Nasal Naloxone which meet the minimum standards established by the Department’s Administrative Requirement 2-100 and are in accordance with the applicable Statewide Treatment Protocols, pursuant to 105 CMR 171.000 (Training);

5. To abide by policies for proper acquisition, storage, replacement, and disposal of the Nasal Naloxone rescue kits approved by the Medical Director and in accordance with the U.S. Food and Drug Administration’s approved manufacturer's product label recommendations (see Amendment A) (acquisition and replacement of devices, shelf life of the medication and proper storage and disposal conditions);

6. To purchase naloxone rescue kits and equip personnel in a manner consistent with Massachusetts’ drug control regulations, including maintaining an active Massachusetts Controlled Substances Registration (MCSR) for municipalities and non-municipal public agencies for use of naloxone in accordance with the Controlled Substances Act, M.G.L. Chapter 94C. Form available at: http://www.mass.gov/eohhs/docs/dph/quality/drugcontrol/naloxone-nerve-antidote-epi-form.pdf (Acquisition and replacement of devices).

7. To work collaboratively with the local ambulance service and fire department to assure continuity of care when transferring overdose victims to the emergency medical service;

8. To provide to the Medical Director, for quality assurance purposes, individual trip record and a summary report of the system-wide database of overdose trip records filed by First Responders, including all First Responder use of Nasal Naloxone; submit summary reports to the Medical Director every quarter (every 3 months) (See Amendment B for sample trip record) (Quality assurance, record keeping);

9. To maintain in a manner reasonably safe from water and fire damage, for a period of not less than seven (7) years, at the main office of the FIRST RESPONDER agency, current, accurate records documenting successful completion of first aid training, including the use of Nasal Naloxone and cardiopulmonary resuscitation training for each First Responder (Record keeping, training);
FIRST RESPONDER
Memorandum of Agreement: For the Use of Nasal Naloxone by First Responders under Massachusetts Statewide Treatment Protocols

It is AGREED TO BY ALL PARTIES:

1. That any party may terminate this Agreement within sixty (60) days written notice.

2. That nothing contained in this Agreement is intended to induce, encourage, solicit, or reimburse the referral of any patient or business, including any patient or business funded in whole or in part by a state or federal health care program, to any party hereunder.

Medical Director

___Alexander Y. Walley, MD, MSc____  _______Medical Director____
Print name  Title

________________________________________  __________________________
Signature  Date

FIRST RESPONDER agency Director/Chief

________________________________________  __________________________
Print name  Title

________________________________________  __________________________
Signature  Date
Amendment A
Acquisition, storage, replacement, and disposal of the Nasal Naloxone rescue kits

**Acquisition** – The components of the nasal naloxone rescue kits will be acquired by the State Police medical unit and assembled into kits that include:

- Two 2 mL Luer-Jet luer-lock syringes prefilled with naloxone (concentration 1mg/mL) [NDC 76329-3369-1]
- Two mucosal atomization devices – Teleflex MAD 300
- One pair of medical gloves
- Information pamphlet with overdose prevention information and step by step instructions for overdose response and naloxone administration.

**Storage** – The nasal naloxone rescue kits should be stored in first aid kits. During extreme hot or cold temperatures or for extended leave time, kits should be removed from vehicles and maintained at room temperature (59-86 degrees F/ 15-30 degrees C) and away from direct sunlight.

**Replacement** - Officers issued nasal naloxone rescue kits will notify the naloxone lead officer when a replacement kit is needed. The naloxone lead officer will place an order for the replacement with the pharmacy supplier for delivery of the replacement kit components to the Medical Unit from whom the officer will receive the replacement kit.

**Disposal** – After use or in the case of breakage, the MAD, syringe, and naloxone vial should be disposed of in a biohazard sharps container.